Lucence is a precision oncology company dedicated to creating state-of-the-art, highly sensitive liquid biopsy tests for early disease detection and personalized treatment selection. Lucence launched its flagship test LiquidHALLMARK, a swift, simple, and sensitive liquid biopsy covering a wide range of clinically relevant biomarkers. Our goal is to provide non-invasive diagnostic options so each patient can receive fast, targeted care. Lucence is headquartered in Palo Alto and Singapore, and its services are delivered worldwide through a CLIA-licensed and CAP-accredited central laboratory.
Visit www.lucence.com for more information, or follow Lucence on Twitter (@LucenceDx)
Lucence will be participating in the ASCO20 Virtual Scientific Program. For information about our upcoming ASCO presentations and webinars or to book a meeting, visit http://lucence.com/asco2020.